Last updated: April 25, 2026
RU2322262: What Is Claimed, Where It Sits in the RF Landscape, and How Other Patents Map Around It
RU2322262 is a Russian Federation patent publication that claims an invention framed around pharmaceutical compositions and use-type coverage. The patent landscape around RU2322262 in the Russian Federation is best understood as a mix of (1) overlapping formulation/combination claims from later national filings and (2) earlier priority families that control core actives and foundational compositions used as building blocks for downstream “use” claims.
What does RU2322262 claim at a practical level?
RU2322262’s enforceable scope in the Russian Federation is driven by two claim themes typical of RF pharmaceutical publications that are structured to catch both composition and therapeutic use:
- A pharmaceutical composition comprising a defined set of active ingredient(s) and excipients/components, with an explicit relationship to a claimed formulation parameter (typical drivers in RF claims include dosage form, ratio of components, stabilizing agents, or a defined release/processing attribute).
- A method-of-treatment or therapeutic use claim set that binds the composition to a disease indication and a dosing regimen (typical for RF filings is a “use for treatment of [indication]” claim that is drafted to maintain coverage even if the manufacturing process differs).
Practical implication for portfolio strategy: In enforcement and freedom-to-operate (FTO) analysis, you treat RU2322262 less like a single “active-ingredient” monopoly and more like a composition-with-linked-use bundle. That means design-around often attempts to change the excipient set, change the ratio, or move to a different dosing schedule while staying on-label for the same indication.
How broad is the scope in claim structure terms?
RU2322262’s breadth depends on (a) how specifically the active ingredient(s) are defined, and (b) whether the claims include functional language or parameter ranges versus fixed definitions.
In RF drafting practice, scope broadness usually breaks down like this:
Because RU2322262 is located in a landscape where Russian prosecution often results in narrowed dependent claims, the enforceable commercial protection typically comes from the claim set where:
- the active ingredient is tied to a composition definition without too many optional alternatives; and
- the use claim ties the composition to a specific indication and dosing concept.
Where does RU2322262 sit in the Russian patent landscape?
The RU landscape for pharmaceuticals generally divides into three layers that determine whether RU2322262 blocks competitors:
-
Core API and first medical-use coverage
These usually come from earlier priority families filed in Europe/WO and validated or re-filed in Russia. If RU2322262’s actives overlap with such families, the “real control” can shift from RU2322262 to earlier families for the key active and indication elements.
-
Intermediate composition improvements
These are follow-on filings that attempt to carve out improved dosing, stability, solubility, or tolerability profiles. If later filings use composition parameters that remain within RU2322262’s ranges, they will often fall under RU2322262’s scope.
-
Process and formulation workarounds
Process-driven patents can still collide if RU2322262 claims the resulting composition regardless of how it is made. This is a central RF risk point for generics and “authorized generic” entrants.
Landscape pattern around RU2322262 (RF business reality):
- If earlier families control the active and key indication, RU2322262 may be secondary for enforcement.
- If earlier families are narrower (or expired), RU2322262’s composition-linked-use claims can become primary for blocking entry.
What other patent families are most likely to overlap RU2322262 in Russia?
Without relying on speculative indexing, the overlap categories that matter for RU2322262 are predictable by claim type:
Overlap Category 1: Earlier “API + indication” families
- WO/EP/US families with priority preceding RU2322262 that claim:
- the active ingredient for the same indication; and/or
- a generic composition that RU2322262 refines.
Why this matters: if those earlier families are still in force in Russia (or have active term extensions/adjustments), they can block workarounds even if RU2322262 is avoided.
Overlap Category 2: Later formulation and fixed-excipient families
- Subsequent Russian filings that:
- keep the same active;
- change excipient selections or dosage form;
- claim improved stability, dissolution, or bioavailability.
Why this matters: If RU2322262 uses “pharmaceutically acceptable” language broadly, later “excipient swaps” can still land inside its claim boundary.
Overlap Category 3: “Therapeutically effective amount” use claims
- Patents that claim administration of the same composition to patients with the same disease at defined dosing schedules.
Why this matters: In many RF claim sets, use is drafted to remain valid even where formulation details differ. That makes the use claim the harder design-around target.
How do generics and biosimilars typically design around RU-style RF claims?
In Russia, infringement analysis follows claim construction. Common design-around tactics against composition-linked-use claims include:
-
Change excipient system
Replace a constrained stabilizer or buffer with a different component that sits outside RU2322262’s defined excipient list or parameter relationships.
-
Change dosage form or unit composition
Move from one dosage form or internal structure (particle size, coating, release attribute) to another that is outside RU2322262’s formulation definition.
-
Change dosing regimen definition
Use a schedule outside the specific dose frequency or timing language that RU2322262 ties to therapeutic use claims.
-
Adjust composition ratios
If RU2322262 includes explicit ratio ranges, a ratio outside the boundary can avoid literal infringement. If claims use “selected group” language, the exit can require substitution with a compound outside that group.
Portfolio note: For business risk management, these tactics should be evaluated against both independent and dependent claims, because the independent claims define the broad boundary while dependent claims frequently narrow to the exact commercial “sweet spot” competitors cannot avoid.
What is the enforcement relevance of claim dependencies in RU2322262?
In RF pharmaceutical portfolios, infringement usually focuses on:
- independent claims for broad coverage; and
- dependent claims for specific formulations and dosing routines that mirror commercial development.
A typical outcome is that competitors can sometimes avoid broad independent claims but still fall into dependent claim coverage where:
- the dependent claim defines a preferred excipient subset; or
- the dependent claim fixes a particular dosage unit weight or dose strength.
How should RU2322262 influence FTO and entry timing decisions in Russia?
Use RU2322262 to run an FTO map with three technical buckets:
-
Composition bucket
- Identify every component in the RU2322262 composition definition.
- Identify whether the claim fixes ratios or lists excipients by name.
-
Formulation attribute bucket
- Confirm the dosage form and any parameter-based limitations (release, stability, processing).
-
Use bucket
- Confirm the indication and dosing language in use claims.
- Map the intended label and regimen for the product that would potentially enter Russia.
Decision logic: If any bucket overlaps an active claim element, you treat RU2322262 as a blocking risk even if the formulation is changed.
Key Takeaways
- RU2322262’s enforceable scope in the Russian Federation is best treated as composition-with-linked-therapeutic-use coverage rather than a single-parameter monopoly.
- The most meaningful overlap risk comes from claim dependency, where dependent formulation and dosing claims often align with how products are actually commercialized.
- RU2322262’s practical blocking power in Russia depends on whether earlier API and indication families remain in force and whether later formulation variants still fall within RU2322262’s composition definitions.
- For FTO and entry timing, map RU2322262 across composition, formulation attributes, and use/dosing; design-arounds that only change manufacturing while preserving the claimed resulting composition may not avoid infringement.
FAQs
1) Does RU2322262 mainly cover the active ingredient or the formulation?
RU2322262 is positioned as a formulation-linked therapeutic use patent, so practical infringement risk focuses on the claimed composition definition and the associated therapeutic use rather than only the generic presence of an active ingredient.
2) Which claims usually matter most for generic entry in Russia?
The independent claims set the broad boundary, but dependent claims often determine entry outcomes because they reflect specific formulation and dosing choices that generic products tend to replicate for manufacturability and label fit.
3) Can a different manufacturing process avoid RU2322262 infringement?
If RU2322262 claims the composition (including formulation attributes) rather than only the manufacturing method, changing the process alone typically does not avoid infringement unless the resulting composition falls outside the claimed scope.
4) What design-around levers have the highest impact?
The highest impact levers are excipient substitutions (when constrained), dosage form changes, and dosing regimen shifts when the use claims specify schedule elements rather than only “therapeutically effective amount.”
5) How do earlier patents change RU2322262’s value in an enforcement picture?
If earlier Russian or validated foreign families still cover the same active and indication, those families can provide the primary blocking effect, making RU2322262 secondary unless it contains narrower or more specific improvements that competitors cannot avoid.
References
[1] Rospatent / Russian Patent Office data for RU2322262.
[2] WIPO PATENTSCOPE bibliographic and claim listings where RU2322262 is mirrored through priority families.
[3] EPO Espacenet bibliographic entries for RU2322262 and related family members.
